TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31015221

Group type: EXPERIMENTAL
Intervention: PHARMS device (intervention group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care, handwritten discharge prescription (control group)
Number of subjects: 102
Study: 28550928

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0.9% normal saline
Number of subjects: 94
Study: 25052626

Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 35
Study: 23221418

Group type: EXPERIMENTAL
Intervention: Topical anesthesia cream (EMLA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20934731

Group type: COMPARATOR
Intervention: Refined olive oil (devoid of phenolic content)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Common olive oil (PC = 370 mmol/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (PC = 825 mmol/kg)
Number of subjects: 33
Study: 19332508

Group type: EXPERIMENTAL
Intervention: Promotion of Acceptance in Carers and Teachers (PACT) workshops over 1.5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 20
Study: 16461044

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 43

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 43
Study: 14996673

Group type: EXPERIMENTAL
Intervention: Antibacterial products
Number of subjects: 238

Group type: COMPARATOR
Intervention: Nonantibacterial products
Number of subjects: 238
Study: 11787719

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with phosphate
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Human milk fortified with protein, calcium, and phosphate
Number of subjects: 127

Group type: COMPARATOR
Intervention: Unsupplemented mother's milk or preterm formula
Number of subjects: 127
Study: 9259870

Group type: EXPERIMENTAL
Intervention: Sufentanil 25 micrograms in saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms in saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Plain prilocaine
Number of subjects: 75
Study: 8508695

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31016340

Group type: EXPERIMENTAL
Intervention: Reduced radiation dose (RD) with −20%, −40%, −57%, or −80% CT radiation dose combined with iterative model‐based reconstruction (IMR) levels 1–3
Number of subjects: 76

Group type: COMPARATOR
Intervention: Full radiation dose (FD) with iterative reconstruction (iDose4)
Number of subjects: 76
Study: 28464211

Group type: EXPERIMENTAL
Intervention: Oral osteoporosis therapy (OPT)
Number of subjects: 7576

Group type: COMPARATOR
Intervention: No osteoporosis therapy (OPT)
Number of subjects: 7576
Study: 25653079

Group type: EXPERIMENTAL
Intervention: Video-game based therapy (VGT) using Xbox with Kinect device for 16 sessions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional therapy (CT) for 16 sessions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Video-game based therapy (VGT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 22
Study: 23629984

Group type: EXPERIMENTAL
Intervention: Foot exercises (n=60)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Thomas crooked and elongated heel with or without arch support (n=45)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rose Schwartz insoles (n=18)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Foot exercises combined with footwear modifications (n=27)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Controls (n=50)
Number of subjects: 150
Study: 22122818

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Benazepril (BENA) 20 mg with HCTZ 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valsartan (VAL) 160 mg with HCTZ 12.5 mg
Number of subjects: 30
Study: 18466655

Group type: EXPERIMENTAL
Intervention: Gum arabic (10 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control (water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive control (10 g inulin)
Number of subjects: 0
Study: 16835028

Group type: EXPERIMENTAL
Intervention: Baby massage for 3 months after delivery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no baby massage)
Number of subjects: 39
Study: 12757433

Group type: EXPERIMENTAL
Intervention: Three-hour educational workshop with supervised hands-on practice
Number of subjects: 800

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 800
Study: 11860828

Group type: EXPERIMENTAL
Intervention: Screening group (RPHA-FOBT and individual quantitative risk assessment model)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 0
Study: 9345019

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 25 mg/kg/d, followed by low-dose maintenance
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Pipobroman (Pi) 1.2 mg/kg/d, followed by low-dose maintenance
Number of subjects: 292

Group type: COMPARATOR
Intervention: Both HU and Pi
Number of subjects: 292
Study: 8445429

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and asparaginase administered at 7-day intervals
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and asparaginase with no maintenance therapy
Number of subjects: 1294

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine and asparaginase intensification
Number of subjects: 1294
Study: 3756365

Group type: COMPARATOR
Intervention: Low-dose IV Metoclopramide (total dose: 0.8 mg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of Metoclopramide plus Nortriptyline (2 X 50 mg PO) plus Thiethylperazine (3 X 10 mg IV)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of Metoclopramide plus Nortriptyline plus Thiethylperazine
Number of subjects: 36
Study: 30388029

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Combination of methylphenidate and behavior therapy
Number of subjects: 576

Group type: COMPARATOR
Intervention: Community care
Number of subjects: 576
Study: 27079434

Group type: EXPERIMENTAL
Intervention: Topiroxostat 120 mg/day
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Topiroxostat 40-120 mg/day
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Topiroxostat 80-120 mg/day
Number of subjects: 187
Study: 25172379

Group type: EXPERIMENTAL
Intervention: BRADA diet (Brazilian Dietary Approach to Break Hypertension), orientation and planned monthly menus, duration 6 months
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care focused on salt intake reduction
Number of subjects: 206
Study: 23759039

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg as a bolus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Metoclopramide 20 mg infused over 15 min
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both groups (bolus and infusion)
Number of subjects: 205
Study: 20726279

Group type: EXPERIMENTAL
Intervention: Eszopiclone (ESZ) 3 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17653697

Group type: EXPERIMENTAL
Intervention: Gaboxadol 20 mg (GBX20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 40
Study: 15515282

Group type: EXPERIMENTAL
Intervention: Educational tool for oral care guidelines
Number of subjects: 0
Study: 11134429

Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement intervention in NICUs (6 NICUs for infection, 4 NICUs for chronic lung disease)
Number of subjects: 3656

Group type: COMPARATOR
Intervention: Control group (9 NICUs)
Number of subjects: 3656

Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement intervention
Number of subjects: 3656
Study: 9555556

Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Raz modification
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Transvaginal Burch
Number of subjects: 146
Study: 7931653

Group type: EXPERIMENTAL
Intervention: One-day protocol with 8 mCi of tetrofosmin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Two-day protocol with 8 mCi of tetrofosmin followed by 24 mCi
Number of subjects: 55
Study: 2466024

Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch‐pentoxifylline (HAES‐steril/Trental)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch‐pentoxifylline‐naftidrofuryl (HAES‐steril/Trental/Dusodril)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: dextran‐pentoxifylline (Rheomacrodex/Trental)
Number of subjects: 394

Group type: COMPARATOR
Intervention: placebo therapy control group (normal saline)
Number of subjects: 394
Study: 31590108

Group type: EXPERIMENTAL
Intervention: Cryotherapy (cooling hands and feet with crushed ice during paclitaxel treatment)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (standard care without cryotherapy)
Number of subjects: 42
Study: 29435591

Group type: COMPARATOR
Intervention: SRRI
Number of subjects: 460

Group type: COMPARATOR
Intervention: SRRI + ETOH
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: SRRI + ETOH + THC
Number of subjects: 460
Study: 27821917

Group type: EXPERIMENTAL
Intervention: Active rehabilitation therapy (two types of rehabilitation programs, four times per week for eight weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no active rehabilitation therapy)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Active rehabilitation therapy
Number of subjects: 16
Study: 24791863

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate (SF; Seretide, GlaxoSmithKline) Diskus (50/500 µg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipratropium bromide/salbutamol (IS; Combivent, Boehringer Ingelheim) MDI (42 µg/240 µg quartic daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate/fluticasone propionate (SF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipratropium bromide/salbutamol (IS)
Number of subjects: 0
Study: 22331829

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg daily
Number of subjects: 6989

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6989
Study: 20157179

Group type: EXPERIMENTAL
Intervention: Periodic presumptive treatment (PPT) followed by syndromic treatment and condom-use promotion
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Periodic presumptive treatment (PPT)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Condom-use promotion
Number of subjects: 580
Study: 17222115

Group type: EXPERIMENTAL
Intervention: IvIg 2 g/kg body weight
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15804151

Group type: EXPERIMENTAL
Intervention: APP and CS
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aprotinin (5,000,000 KIU Trasylol)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of APP, CS, and Aprotinin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 70
Study: 12584830

Group type: EXPERIMENTAL
Intervention: Shenle capsule (SLC)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: SLC plus benazepril
Number of subjects: 142

Group type: COMPARATOR
Intervention: benazepril (Control)
Number of subjects: 142
Study: 10613620

Group type: EXPERIMENTAL
Intervention: Tramadol 200 to 400 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 7577277

Group type: EXPERIMENTAL
Intervention: Single intrathoracic block of four intercostal nerves
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous thoracic extradural infusion of bupivacaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Continuous paravertebral infusion of bupivacaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 1785269

Group type: EXPERIMENTAL
Intervention: Intracervical gel with 0.5 mg PGE2 (n = 116)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Vagitories containing 2.5 mg PGE2 (n = 110)
Number of subjects: 226
Study: 7261924

Group type: EXPERIMENTAL
Intervention: Tracheotomy after a variable time of intubation (Group II)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tracheotomy immediately (Group III)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Long-term intubation (Group I)
Number of subjects: 77
Study: 30706439

Group type: EXPERIMENTAL
Intervention: Early closure (8‐13 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Late closure (after 12 weeks)
Number of subjects: 112
Study: 28314866

Group type: EXPERIMENTAL
Intervention: attrition plus ALA-PDT
Number of subjects: 60

Group type: COMPARATOR
Intervention: single ALA-PDT treatment
Number of subjects: 60
Study: 25468473

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 23582009

Group type: EXPERIMENTAL
Intervention: Low-dose Epo (63 IU/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-dose Epo (400 IU/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Putative mediators of hepcidin repression (transferrin saturation, soluble transferrin receptor, growth differentiation factor 15)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Soluble hemojuvelin
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Skeletal muscle tissue
Number of subjects: 14
Study: 21358718

Group type: EXPERIMENTAL
Intervention: SpeediCath Compact Male
Number of subjects: 37

Group type: COMPARATOR
Intervention: SpeediCath
Number of subjects: 37
Study: 19741408

Group type: EXPERIMENTAL
Intervention: PHIO catheter placement
Number of subjects: 91

Group type: COMPARATOR
Intervention: PIV catheter placement
Number of subjects: 91

Group type: COMPARATOR
Intervention: CVC catheter placement
Number of subjects: 91
Study: 17728422

Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) for 8 weeks, followed by citalopram if insufficient response
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nonresponders to antidepressant treatment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Untreated control subjects
Number of subjects: 168
Study: 15499897

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccination (4 microg)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccination (20 microg)
Number of subjects: 143
Study: 11181776

Group type: EXPERIMENTAL
Intervention: HPV testing (Hybrid Capture 2)
Number of subjects: 3488

Group type: EXPERIMENTAL
Intervention: Single repeat cytology with HSIL threshold
Number of subjects: 3488

Group type: EXPERIMENTAL
Intervention: Single repeat cytology with ASCUS threshold
Number of subjects: 3488

Group type: COMPARATOR
Intervention: Immediate colposcopy (reference standard)
Number of subjects: 3488
Study: 9820611

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of recombinant human erythropoietin (rhEPO) at a flow rate of 6000 IU per week (36 IU/h)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of recombinant human erythropoietin (rhEPO)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Weekly bolus subcutaneous injection of recombinant human erythropoietin (rhEPO) at a dose of 6000 IU
Number of subjects: 5
Study: 8584530

Group type: EXPERIMENTAL
Intervention: salbutamol 0.2 mg (test effect)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: fenoterol 0.2 mg, salbutamol 0.2 mg, salmeterol 0.05 mg (best effect)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: beta 2‐agonist (TGV reduction)
Number of subjects: 15
Study: 2196261

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 0
Study: 159067

Group type: EXPERIMENTAL
Intervention: Fentanyl as part of the anaesthetic technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 0
Study: 31369510

Group type: EXPERIMENTAL
Intervention: Posterior pharyngeal fat grafting
Number of subjects: 167
Study: 30842028

Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor with alarms activated after 6 months
Number of subjects: 907

Group type: COMPARATOR
Intervention: Control group (alarms deactivated)
Number of subjects: 907
Study: 27602992

Group type: EXPERIMENTAL
Intervention: Structured and therapist-guided internet intervention based on solution-focused and cognitive-behavioral therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 39
Study: 26052657

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Congregate Housing (CONG)
Number of subjects: 597
Study: 23558871

Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin (Group 1, n = 60) - 80 mg daily aspirin orally and 5000 U unfractionated heparin per 8 h subcutaneously from admission to discharge.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heparin alone (Group 2, n = 60) - same dose of heparin alone.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin plus heparin (Group 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heparin alone (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 20130074

Group type: EXPERIMENTAL
Intervention: Universal screening group
Number of subjects: 4562

Group type: COMPARATOR
Intervention: Case-finding group
Number of subjects: 4562
Study: 19001832

Group type: EXPERIMENTAL
Intervention: Tailored face-to-face counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phone counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerized tailored feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-based health behavior assessment with feedback and education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions in general
Number of subjects: 0
Study: 16157399

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg bid
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg od
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 255
Study: 12636943

Group type: EXPERIMENTAL
Intervention: Sleeved cytobrush
Number of subjects: 62

Group type: COMPARATOR
Intervention: Endocervical curette
Number of subjects: 62
Study: 11192711

Group type: EXPERIMENTAL
Intervention: E5510 (4 mg x day(-1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no anti-thrombotic medication)
Number of subjects: 15
Study: 8642829

Group type: EXPERIMENTAL
Intervention: pH‐stat management during cardiopulmonary bypass
Number of subjects: 70

Group type: COMPARATOR
Intervention: alpha‐stat management during cardiopulmonary bypass
Number of subjects: 70
Study: 1686581

Group type: EXPERIMENTAL
Intervention: Glutamic acid hydrochloride (two 680-mg doses given 10 minutes apart)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Glutamic acid hydrochloride (two 680-mg doses given 10 minutes apart) after ranitidine 300 mg (administered 1-2 hours prior)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ranitidine 300 mg (as hydrochloride salt)
Number of subjects: 6
Study: 6383993

Group type: EXPERIMENTAL
Intervention: Three-phase preparation containing levonorgestrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monophasic combination preparations (levonorgestrel and desogestrel)
Number of subjects: 0
Study: 31740476

Group type: EXPERIMENTAL
Intervention: eCBTI via a Smartphone application
Number of subjects: 200

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study: 29775985

Group type: EXPERIMENTAL
Intervention: Sensorimotor Training (SMT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 43
Study: 27955688

Group type: EXPERIMENTAL
Intervention: Remifentanil PCA
Number of subjects: 400

Group type: COMPARATOR
Intervention: Pethidine intramuscular injection
Number of subjects: 400
Study: 24773166

Group type: EXPERIMENTAL
Intervention: Ondansetron 0.5 mg/d
Number of subjects: 77

Group type: COMPARATOR
Intervention: Sertraline 200 mg/d
Number of subjects: 77
Study: 22932119

Group type: EXPERIMENTAL
Intervention: 50 mg lixivaptan once daily, titrated to 25-100 mg once daily depending on serum sodium concentration
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 20178636

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT), 3 sessions per week for up to 6 weeks, total up to 18 sessions.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Algorithm-based pharmacological treatment as usual.
Number of subjects: 132
Study: 17632760

Group type: EXPERIMENTAL
Intervention: Immunoenriched formula (Impact) for 5 days preoperatively
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Immunoenriched formula (Impact enriched with glycine) for 2 days preoperatively
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (Impact for 7 days postoperatively, no preoperative treatment)
Number of subjects: 46
Study: 16547345

Group type: COMPARATOR
Intervention: Preoperative fMRI session with verbal task
Number of subjects: 24

Group type: COMPARATOR
Intervention: Preoperative fMRI session with nonverbal task
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Postoperative fMRI session in left TLE patients
Number of subjects: 24